FDA accepts Supplemental New Drug Application for Nurtec (rimegepant) orally disintegrating tablet (ODT) for preventive treatment of migraine

Rimegepant is already approved in US for acute treatment of migraine. Licence extension application is based on data from prevention trial which showed patients on 75 mg every other day experienced statistically significant 4.3 day reduction from baseline in monthly migraine days

Source:

Biospace Inc.